Mental Health Book

http://www.fpnotebook.com/

ImipramineAka: Tofranil

Advertisement

  1. Indications
    1. Panic Disorder
    2. Pediatric Major Depression
    3. Attention Deficit Hyperactivity Disorder
    4. Nocturnal Enuresis (not first line agent)
  2. Dosing: General
    1. Adult: 25-50 mg PO qhs
  3. Dosing: Nocturnal Enuresis in children
    1. Consider other measures for Nocturnal Enuresis first
    2. Initial dose
      1. Age 6-8 years: 25 mg PO one hour before bedtime
      2. Age 8-12 years: 50 mg PO one hour before bedtime
      3. Age over 12 years: 75 mg PO one hour before bedtime
    3. Maximum dosing: up to 0.9 to 1.5 mg/kg
    4. Discontinue after 3-6 months
      1. Taper to one half dose nightly for 2 weeks
      2. Taper to one half dose every other night for 2 weeks
  4. Pharmacokinetics
    1. Obtain serum levels in pediatric population
    2. Avoid as full dose Antidepressant
    3. Serum Half Life: 11 to 25 hours
    4. Therapeutic plasma level: 200 to 350
  5. Adverse effects
    1. See Tricyclic Antidepressants
    2. Significant adverse effects
      1. Anticholinergic Symptoms
      2. Orthostatic Hypotension
      3. Cardiac arrhythmia
      4. Weight gain
  6. Precautions
    1. See Tricyclic Antidepressants
    2. Serious cardiotoxicity in overdosage
  7. References
    1. Thiedke (2003) Am Fam Physician 67:1499

Imipramine (C0020934)

Definition (MSH)The prototypical tricyclic antidepressant. It has been used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. It has less sedative effect than some other members of this therapeutic group.
Definition (CSP)dibenzazepine tricyclic antidepressant.
Definition (NCI)A synthetic tricyclic derivative, antidepressant Imipramine enhances monoamine neurotransmission in certain areas of the brain. It also induces sedation through histamine 1 receptor blockage; hypotension through beta-adrenergic blockage; and diverse parasympatholytic effects. Imipramine has less sedative effect than other members of its therapeutic family. It is used in major depression, dysthymia, bipolar depression, attention-deficit disorders, agoraphobia, and panic disorders. (NCI04)
ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD007099
EnglishImidobenzyle, Imipramine, IMIPRAMINE PREPARATION, Imizin, Norchlorimipramine
Spanishimipramina
Parent ConceptsAminoacridines (C0002536), Antidepressive Agents, Tricyclic (C0003290), Azepines (C0004484), Dibenzazepines (C0012029), Antidepressive Agents (C0003289)
SourcesAOD, CSP, LCH, LNC, MSH, MTH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF
Derived from the NIH UMLS (Unified Medical Language System)


Tofranil (C0025231)

ConceptsOrganic Chemical (T109) , Pharmacologic Substance (T121)
MSHD007099
EnglishTofranil
SourcesMSH, NCI, RXNORM
Derived from the NIH UMLS (Unified Medical Language System)



Navigation Tree